Maxim A Kriventsov

Dr. Maxim A Kriventsov

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DEDarya Enzel
Darya Enzel
MKMaxim A Kriventsov
Maxim A Kriventsov
TSTatiana Sataieva
Tatiana Sataieva
VMVeronika Malygina
Veronika Malygina
Idiopathic pulmonary fibrosis remains a relevant problem of the healthcare system with an unfavorable prognosis for patients due to progressive fibrous remodeling of the pulmonary parenchyma. Starting with the damage of the epithelial lining of alveoli, pulmonary fibrosis is implemented through a cascade of complex mechanisms, the crucial of which is the TGF-β/SMAD-mediated pathway, involving various cell populations. Considering that a number of the available drugs (pirfenidone and nintedanib) have only limited effectiveness in slowing the progression of fibrosis, the search and justification of new approaches aimed at regulating the immune response, cellular aging processes, programmed cell death, and transdifferentiation of cell populations remains relevant. This literature review presents the key modern concepts concerning molecular genetics and cellular mechanisms of lung fibrosis development, based mainly on in vitro and in vivo studies in experimental models of bleomycin-induced pulmonary fibrosis, as well as the latest data on metabolic features, potential targets, and effects of vitamin D and its metabolites.

3 October 2023 in Journal of Periodontal Research
Verified
Journal Article
Closed access
ONOlga A. Neprelyuk
Olga A. Neprelyuk
SZSergey I. Zhad'KO
Sergey I. Zhad'KO
ИРИнесса Романенко
Инесса Романенко
MKMaxim A Kriventsov
Maxim A Kriventsov

30 March 2021 in Russian Open Medical Journal
Verified
Journal Article
Closed access
UBUsein I. Basnaev
Usein I. Basnaev
NKNariman E. Karakursakov
Nariman E. Karakursakov
VMVyacheslav Yu. Mykhaylichenko
Vyacheslav Yu. Mykhaylichenko
MKMaxim A Kriventsov
Maxim A Kriventsov
Background — According to the data from the published sources worldwide, about 10% of the world population suffers from osteoarthrosis. While searching for novel methods of osteoarthrosis treatment, we proposed administering intra-articular injections of autologous platelet-rich plasma. The goal of this clinical study was to evaluate the effectiveness of autologous platelet-rich plasma injections in osteoarthrosis patient treatment. Methods — This open-label parallel-group study was a pilot randomized controlled trial. An analysis of the treatment outcomes for 128 patients with knee joint arthrosis was performed. All patients were split among three groups, and subjects in two of those were receiving conventional treatment. Clinical efficacy was calculated from pain intensity, determined using Visual Analog Scale, Lequesne index and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Inflammatory response intensity was assessed by superoxide dismutase content and erythrocyte catalase activity. Results — It was demonstrated that administering platelet-rich plasma allowed achieving tangible clinical and laboratory results without any side effects and with very few contraindications. The latter included, for instance, blocking inflammatory process in the joints, thereby inhibiting the oxidative stress, which is the most pathogenetically substantiated treatment of osteoarthrosis. Conclusion — Thus, we have discovered that platelet-rich plasma injections had apparent anti-inflammatory and pain-relieving effects, along with inhibiting action of destructive processes in the cartilaginous tissue, hence improving life quality of the patients with osteoarthrosis.

1 January 2018 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
SKS. A. Kutia
S. A. Kutia
NPN. Yu. Printzeva
N. Yu. Printzeva
YRYe. A. Razumovskaya
Ye. A. Razumovskaya
NSN. A. Shaposhnick
N. A. Shaposhnick
MKMaxim A Kriventsov
Maxim A Kriventsov
ЕРЕ. А. Разумовская
Е. А. Разумовская
Medical article медицинская статья

1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
SKS. A. Kutia
S. A. Kutia
VKV. V. Kiselev
V. V. Kiselev
VPV. S. Pikaliuk
V. S. Pikaliuk
GMG. A. Moroz
G. A. Moroz
MKMaxim A Kriventsov
Maxim A Kriventsov
Medical article медицинская статья

1 January 2019
Verified
Open access
AGAlina Vitalievna Gerashchenko
Alina Vitalievna Gerashchenko
TFTatyana Grygorievna Filonenko
Tatyana Grygorievna Filonenko
EGElena Petrovna Golubinskaya
Elena Petrovna Golubinskaya
MKMargarita Alexeevna Kalfa
Margarita Alexeevna Kalfa
MKMaxim A Kriventsov
Maxim A Kriventsov
Leiomyomatosis peritonealis disseminata (LPD) is a benign disease characterized by the presence of multiple small nodules on the omentum, parietal, and visceral peritoneum. It corresponds to leiomyoma and often resembles metastases of malignant tumors; however, with favorable prognosis. Here we describe a 46-year-old woman, diagnosed with LPD, to demonstrate the etiopathogenesis of the developed leiomyomatosis following endoscopic extirpation of the uterus with the use of a power morcellator. The patient was operated for diffuse leiomyoma using a power morcellator. Six months later, during a follow-up visit, disseminated tumornodes on the peritoneum were revealed. Histological and immunohistochemical (smooth muscle a-actin, vimentin, estrogen receptors, progesterone receptors, and Ki67) study confirmed the diagnosis of LPD. As part of the follow-up, certain regression of the tumor nodes was noted against the backdrop of the onset of menopause and the corresponding decline of estrogen levels. Currently, the prognosis is favorable and follow-up is ongoing. Such cases are rare, but the condition is particularly important due to its iatrogenic nature. It has attracted the attention of the Food and Drug Administration (FDA) because power morcellation is probably associated with the risk of spreading suspected cancerous tissue. The existing high risk of iatrogenic LPD formation indicates the need for detailed reporting of all similar clinical cases, including the established pathogenetic and pathomorphological mechanisms of this process to prevent morcellator-related complications.